Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cullinan Amber Corp. has 1 pending office action in Biotechnology & Pharmaceuticals. The matter is associated with 1 distinct examiner and 1 distinct art unit, resulting in one examination route.
CESARE, JOSEPH DAVID is the busiest examiner, with 1 pending matter. The available data supports an application-specific prosecution plan focused on the outstanding grounds and claim support. It does not show additional examiner or art-unit activity requiring portfolio coordination.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CESARE, JOSEPH DAVID | 1 | — | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18257177 | BI-FUNCTIONAL LINEAR FUSION COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF | CESARE, JOSEPH DAVID | 1675 | §103 | Final Rejection | — | Pending | Jun 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCullinan Amber Corp. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Joseph David Cesare has the most, with 1 of Cullinan Amber Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
